Ariel Y. Deutch was trained as a psychologist, and then did postdoctoral training in neuropharmacology at Yale University.  He remained at Yale for almost 15 years as a faculty member before moving to Vanderbilt University in 1997.  His primary interests are in the non-motor symptoms of Parkinson’s disease, especially depression and cognitive deficits, and in understanding the dysfunction of extended corticofugal circuits emanating from different sets of pyramidal cells in the prefrontal cortex, in both parkinsonism and schizophrenia.  Dr. Deutch is on the editorial boards of a number of journals, including Neuropsychopharmacology (Deputy Editor) and The Lancet Neurology, and has been a standing member of five NIH study sections, including chair of the Molecular Neuropharmacology and Signaling (MCDC-5) committee.  He is a member of the Scientific Council of the Brain and Behavior Foundation (NARSAD), and chair of the Clinical and Scientific Advisory Board of the National Parkinson Foundation.